# Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

> **NCT00482495** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 42 (estimated)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **BIOLOGICAL:** bevacizumab
- **GENETIC:** gene expression analysis
- **GENETIC:** protein expression analysis
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00482495
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2006-12
- **Final completion:** 2009-11
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2011-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00482495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00482495, "Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00482495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*